Dysfunctional Uterine Bleeding Market– Growing awareness likely to result in handsome CAGR growth
The Global Dysfunctional Uterine Bleeding Market
Synopsis:
Dysfunctional uterine bleeding (DUB) is
abnormal genital tract bleeding based in the uterus without the presence of any
structural or organic disease. Although the exact reason is unknown, it is
usually a menstrual disorder due to hormonal disturbances such as reduced
progesterone levels, increased levels of tissue plasminogen activator and
others. However there are cases of abnormal bleeding from the uterus outside
menstruation. The global Dysfunctional Uterine Bleeding
Market is expected to grow at a CAGR of 7.6 %
during the forecast period of 2017 to 2023
DUB is classified as ovulatory or
anovulatory, depending on whether ovulation is occurring or not. 10% of cases
occur in women who are ovulating, called as ovulatory DUB. About 90% of DUB is
anovulatory with events occur when ovulation is not occurring and is common at
the extremes of reproductive age, such as early puberty and perimenopause. The risk
factors are psychological stress, weight changes such as obesity, anorexia,
heavy exercise, endocrinopathy, neoplasm, drugs, etc. increasing cases of fibroids
in the uterus, infection of the cervix, cancer of the uterus, polycystic ovary
syndrome, endometriosis, and uterine polyps are also firing the growth of the
market. According to the World Cancer Research Fund International, endometrial
cancer is the sixth most common cancer in women worldwide, in 2015, with 53% of
endometrial cancer cases occurring in the developed countries.
Key Players in the Global Dysfunctional Uterine
Bleeding Market
·
B. Braun Melsungen AG
·
Hologic Inc
·
Karl Storz Gmbh & Co. KG
·
Medgyn Products
·
Olympus
·
Richard Wolf GmbH
·
Stryker
·
Xion Medical GmbH
·
Cadila Pharmaceuticals Ltd
·
Torrent Phamraceuticals
Segments of the Global Dysfunctional Uterine
Bleeding Market
·
Dysfunctional uterine
bleeding market is segmented into type, diagnosis, and treatment.
·
On the basis of type the
market is sub-segmented into ovulatory and anovulatory.
·
On the basis of diagnosis,
the market is sub-segmented into physical examination, hysteroscopy,
ultrasonography, blood tests and others.
·
On the basis of treatment the market is sub-segmented into pharmacologic
treatment, hysterectomy, endometrial ablation and others.
Regional outlook of the dysfunctional uterine
bleeding market
America is the largest market for
dysfunctional uterine bleeding market across the globe. The market is driven by
the rising prevalence of uterine cancer and other uterine disorders among
women. According to the American Cancer Institute, about 61,380 new cases of
uterine cancer is estimated to be diagnosed in 2017. Europe is the second
largest market owing to an increasing demand for diagnosis and treatment
measures for uterine cancer, fibroids and other disorders, and increasing
emphasis on women healthcare.
The market in Asia Pacific
is expected to grow at the fastest pace and is driven by the increasing
prevalence of menstrual disorders, rising awareness about causes of such
disorders and early diagnosis and treatment measures among women. The market is
also driven by rising prevalence of sexually transmitted diseases among women
in the developing nations. Rising awareness is the key to the market as a large
unmet need is present in the developing regions which has not been tapped due
to the stigma associated with women gynaecological disorders.
Comments
Post a Comment